The other day when I sat down at my computer, I discovered a small, beige envelope that had been left near my workspace. To my surprise, inside was a letter addressed to me from the rollator that helps me live with ALS. After a quick read of the note,…
A rollator speaks — with a special request
The Muscular Dystrophy Association (MDA) will celebrate the 25th anniversary on June 25 of its Wings Over Wall Street Gala, an annual fundraiser to support research for amyotrophic lateral sclerosis (ALS). The event will take place at the Edison Ballroom in New York City, starting at 6…
Researchers have discovered a pathway in cells that prevents the formation of TDP-43 protein clumps, which contribute to nerve cell damage in nearly all people with amyotrophic lateral sclerosis (ALS). The findings may aid ALS therapies that can activate the pathway and potentially limit TDP-43 clumping and prevent nerve…
A neurosurgeon and his team from the University of California (UC) Davis Health have won The Herbert Pardes Clinical Research Excellence Award — given by the nonprofit Clinical Research Forum — for their work on a brain-computer interface that translates brain signals into speech with greater than 95% accuracy.
Sometime in my mid-40s, I wrote a list of goals I wanted to achieve before turning 50. I no longer have the list, but I remember a few things on it: Learn a second language. Complete one half-marathon each year. And my then-favorite, visit 50 countries by the time I…
Treatment with regulatory T-cells, or Tregs — a type of anti-inflammatory immune cell — was well tolerated and seemed to slow disease progression in a small clinical trial that enrolled six people with amyotrophic lateral sclerosis (ALS). The work was conducted by scientists at Columbia University in New…
Signs of spring appear every day outside my kitchen window here in northern Michigan, even as my own life feels heavy with my care for my husband, Todd, who has ALS. After a long winter, our 2 feet of snow, which was in the field behind our house a…
The U.S. Food and Drug Administration (FDA) has given Xellsmart Biopharmaceutical the go-ahead to start a Phase 1 clinical trial testing its stem cell-based therapy XS-228 in people with amyotrophic lateral sclerosis (ALS). This milestone, reflecting the approval of Xellsmart’s investigational new drug (IND) application, follows promising results…
Some days, my motivation just gets stuck. Even though I’ve got interesting plans and projects to do, I can’t get started on any of them. The reasons why can include not getting enough hours of sleep the night before, being caught up in the latest news cycle, or simply reflecting…
A combination of three drugs — one of them the experimental therapy CuATSM — may be effective for treating amyotrophic lateral sclerosis (ALS) caused by mutations in the SOD1 gene, according to a new preclinical study. In mice carrying SOD1 mutations, the combination of these three drugs — CuATSM,…
Recent Posts
- Dealing with loss, both big and small, in life with ALS
- Scientists use fat-based ‘bubbles’ to sneak ALS treatment into the brain
- Guest Voice: ALS hasn’t stopped this go-to guy from showing up as ‘Dad’
- HEALEY ALS platform trial launches new arm testing oral therapy NUZ-001
- Ahead of this year’s MDA Conference, association’s CEO speaks of ‘hope’